Related Experiment Video
Updated: Jun 25, 2026
14:52
Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
Published on: December 11, 2013
Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data
T De Backer1, R Vander Stichele, P Lehert
1Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium. tine.debacker@Ugent.be
BMJ (Clinical Research Ed.)
|March 12, 2009
Summary
Naftidrofuryl significantly improves walking distance for individuals with intermittent claudication. This meta-analysis confirms its clinical effectiveness compared to placebo, offering a valuable treatment option.
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Intermittent claudication is a common symptom of peripheral artery disease, significantly impacting patients' quality of life.
- Limited effective pharmacological treatments exist for improving walking capacity in these patients.
Purpose of the Study:
- To evaluate the efficacy of naftidrofuryl in alleviating intermittent claudication symptoms.
- To compare the effects of naftidrofuryl against a placebo using individual patient data.
Main Methods:
- A comprehensive meta-analysis of individual patient data from double-blind, randomized controlled trials.
- Inclusion criteria focused on patients with intermittent claudication receiving oral naftidrofuryl or placebo, with pain-free walking distance as the primary outcome.
- Data were collected from multiple databases including Medline, Embase, and Cochrane registers, with intention-to-treat analysis.
Main Results:
- The analysis included 1266 randomized patients, with 1083 in the primary analysis.
- Naftidrofuryl demonstrated a 1.37-fold improvement in pain-free walking distance compared to placebo (95% CI: 1.27-1.49).
- A significant difference in response rate (22.3%) and a number needed to treat of 4.48 were observed.
Conclusions:
- Naftidrofuryl provides a clinically meaningful improvement in walking distance for patients suffering from intermittent claudication.
- This meta-analysis supports naftidrofuryl as an effective therapeutic option for managing this condition.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
01:26Peripheral Artery Disease IV: Nursing Management
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...